Working… Menu

Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00546988
Recruitment Status : Unknown
Verified October 2007 by University of Wuerzburg.
Recruitment status was:  Recruiting
First Posted : October 19, 2007
Last Update Posted : October 19, 2007
Information provided by:
University of Wuerzburg

Brief Summary:
The study is evaluating whether risk-stratification by the means of a chromosomal aberration provides a tool to discriminate between standard and high risk. Risk-adapted therapy is based on allogeneic stem-cell transplantation for high-risk subjects instead of a second autograft in patients with deletion of chromosome 13 who have an HLA-identical stem cell donor available.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Biological: allogeneic stem cell transplant Phase 3

Detailed Description:
The DSMM V protocol is to compare a consolidation treatment for standard-risk patients not displaying del(13) at initial diagnosis following two cycles of high-dose melphalan 200 mg/m² each supported by autologous stem cell retransfusion with interferon versus PEG-interferon. Patients with del(13) are screened for availability of a fully HLA-matched related or unrelated donor. If patient's informed consent is obtained additionally, he is scheduled to undergo an allogeneic SCT following the first cycle of high-dose melphalan. All other subjects are to proceed to a second course of high-dose melphalan similar to the standard-risk group. Initial cytoreduction is foreseen with four cycles of anthracycline-dexamethasone combination followed by combination therapy with ifosfamide/epirubicine/etoposide for stem-cell collection.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multizentrische Therapiestudie Des Multiplen Myeloms DSMM V Therapieoptimierungs-Studie Der Deutschen Studiengruppe Multiples Myelom für Patienten Bis 60 Jahre im Stadium II/III
Study Start Date : October 2001
Estimated Study Completion Date : January 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
No Intervention: Standard risk IFN
Administration of interferon alpha as a maintenance treatment following autologous stem cell transplantation
No Intervention: Standard risk PEGIFN
Maintenance treatment with pegylated interferon following autologous stem cell transplantation
Experimental: High risk allo
Allogeneic stem cell transplantation from an HLA identical related or unrelated donor
Biological: allogeneic stem cell transplant
No Intervention: High risk auto
Second cycle of high-dose melphalan in subjects without an HLA-identical donor

Primary Outcome Measures :
  1. Response rate after high-dose therapy [ Time Frame: one year ]

Secondary Outcome Measures :
  1. Response rate and treatment-related mortality after allogeneic transplantation [ Time Frame: one year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Primary diagnosis of multiple myeloma
  • Salmon-and-Durie stage II or III
  • Less than or equal to 60 years
  • Signed informed consent

Exclusion Criteria:

  • Relevant comorbidities
  • Unable to adhere to study protocol
  • Pregnancy
  • Not received subject's informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00546988

Layout table for location contacts
Contact: Hermann Einsele, M.D. +49/931/201-0 ext 70015
Contact: Stefan Knop, M.D. +49/931/201-0 ext 70368

Layout table for location information
Medizinische Univ.-Klinik Graz Recruiting
Graz, Austria, 8036
Contact: Werner Linkesch, MD    ++43(0)316/385-4086   
Principal Investigator: Werner Linkesch, MD         
Klin. Abt. für Onkologie, AKH Wien Recruiting
Vienna, Austria, 1090
Contact: Johannes Drach, MD   
Principal Investigator: Johannes Drach, MD         
Staedtisches Klinikum Recruiting
Augsburg, Germany, 86156
Dept. of Hematology/Oncology, Charité Berlin Recruiting
Berlin, Germany, 10098
Contact: Orhan Sezer, MD    030/450-513105   
Principal Investigator: Orhan Sezer, MD         
Charité University Medicine Recruiting
Berlin, Germany, 10117
Contact: Orhan Sezer, M.D.   
University Hospital Recruiting
Erlangen, Germany, 91054
Krankenhaus Nordwest Recruiting
Frankfurt, Germany, 60488
Freiburg University Hospital Recruiting
Freiburg, Germany, 79106
Contact: Monika Engelhardt, M.D.   
Georg August University Hospital Recruiting
Gottingen, Germany, 37075
Ernst-Moritz Arndt University Hospital Recruiting
Greifswald, Germany, 17478
Martin-Luther University Hospital Recruiting
Halle/Saale, Germany, 06120
Contact: Hans H Wolf, M.D.   
University Hospital Eppendorf Recruiting
Hamburg, Germany, 20246
Hannover Medical School Recruiting
Hannover, Germany
Contact: Dietrich Peest, M.D.    +49/511-532-0 ext -27765   
Saarland University Hospital Recruiting
Homburg/Saar, Germany, 66421
Contact: Michael Pfreundschuh, M.D.    +49/6841-162-0 ext 3003   
Schleswig-Holstein University Hospital Recruiting
Lubeck, Germany, 23538
Mainz University Hospital Recruiting
Mainz, Germany, 55131
Dept. of Internal Medicine A, University Muenster Recruiting
Muenster, Germany, 48129
Contact: Martin Kropff, MD   
Sub-Investigator: Martin Kropff, MD         
Dept. of Internal Medicine, Ludwig-Maximilian-University Munich Recruiting
Munich, Germany, 80336
Contact: Christian Straka, MD    089/5160-2278   
Principal Investigator: Christian Straka, MD         
Klinikum rechts der Isar Recruiting
Munich, Germany, 81675
Nuremberg Central Hospital Recruiting
Nuremberg, Germany
Contact: Hannes Wandt, M.D.    +49/911/398-0 ext 3090   
Oldenburg Hospital Recruiting
Oldenburg, Germany, 26133
Contact: Bernd , Metzner    +49/441/403-0 ext 2376   
University Hospital Recruiting
Regensburg, Germany, 93053
Katharinenhospital Recruiting
Stuttgart, Germany, 70173
Contact: Hans G Mergenthaler, M.D.    +49/711/253-0 ext 2501   
Diakonissenkrankenhaus Recruiting
Stuttgart, Germany, 70176
Tubingen University Hospital Recruiting
Tubingen, Germany, 72076
Contact: Katja Weisel, M.D.    +49/7071/29-0 ext -82711   
Dept. of Internal Medicine III, University of Ulm Recruiting
Ulm, Germany, 89081
Contact: Peter Liebisch, MD    0731/500-33809   
Principal Investigator: Peter Liebisch, MD         
Ulm University Hospital Recruiting
Ulm, Germany, 89081
Horst-Schmidt-Kliniken Recruiting
Wiesbaden, Germany, 65199
Contact: Norbert Frickhofen, M.D.    +49/611/43-0 ext 3009   
Dept. of Internal Medicine II, University of Wuerzburg Recruiting
Wuerzburg, Germany, 97070
Contact: Hermann Einsele, MD    +4993120170011   
Sub-Investigator: Volker Kunzmann, MD         
Sub-Investigator: Stefan Knop, MD         
Sponsors and Collaborators
University of Wuerzburg
Layout table for investigator information
Principal Investigator: Hermann Einsele, M.D. Wuerzburg University Hospital, Dept. of Hematology and Oncology

Additional Information:
Layout table for additonal information Identifier: NCT00546988     History of Changes
Other Study ID Numbers: DSMM V
First Posted: October 19, 2007    Key Record Dates
Last Update Posted: October 19, 2007
Last Verified: October 2007
Keywords provided by University of Wuerzburg:
primary treatment
allogeneic stem-cell transplantation
high-dose therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases